JP7452880B2 - Ssx2抗原を識別するt細胞受容体 - Google Patents

Ssx2抗原を識別するt細胞受容体 Download PDF

Info

Publication number
JP7452880B2
JP7452880B2 JP2021517352A JP2021517352A JP7452880B2 JP 7452880 B2 JP7452880 B2 JP 7452880B2 JP 2021517352 A JP2021517352 A JP 2021517352A JP 2021517352 A JP2021517352 A JP 2021517352A JP 7452880 B2 JP7452880 B2 JP 7452880B2
Authority
JP
Japan
Prior art keywords
tcr
seq
amino acid
chain
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021517352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502056A5 (cg-RX-API-DMAC7.html
JP2022502056A (ja
Inventor
イ リ
ジン フ
ジュン リ
ハンリ スン
Original Assignee
エックスライフエスシー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックスライフエスシー リミテッド filed Critical エックスライフエスシー リミテッド
Publication of JP2022502056A publication Critical patent/JP2022502056A/ja
Publication of JP2022502056A5 publication Critical patent/JP2022502056A5/ja
Application granted granted Critical
Publication of JP7452880B2 publication Critical patent/JP7452880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021517352A 2018-09-26 2019-09-20 Ssx2抗原を識別するt細胞受容体 Active JP7452880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811123747.0A CN110950949B (zh) 2018-09-26 2018-09-26 一种识别ssx2抗原的t细胞受体
CN201811123747.0 2018-09-26
PCT/CN2019/107097 WO2020063488A1 (zh) 2018-09-26 2019-09-20 一种识别ssx2抗原的t细胞受体

Publications (3)

Publication Number Publication Date
JP2022502056A JP2022502056A (ja) 2022-01-11
JP2022502056A5 JP2022502056A5 (cg-RX-API-DMAC7.html) 2022-09-29
JP7452880B2 true JP7452880B2 (ja) 2024-03-19

Family

ID=69949278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517352A Active JP7452880B2 (ja) 2018-09-26 2019-09-20 Ssx2抗原を識別するt細胞受容体

Country Status (6)

Country Link
US (1) US11649270B2 (cg-RX-API-DMAC7.html)
EP (1) EP3858852B1 (cg-RX-API-DMAC7.html)
JP (1) JP7452880B2 (cg-RX-API-DMAC7.html)
CN (1) CN110950949B (cg-RX-API-DMAC7.html)
CA (1) CA3114451A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020063488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力t细胞受体
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114524870A (zh) * 2020-11-23 2022-05-24 香雪生命科学技术(广东)有限公司 源自于ssx2抗原的短肽
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500002A (ja) 2010-09-21 2014-01-09 アメリカ合衆国 抗ssx−2t細胞受容体及び関連材料並びに使用方法
JP2016523268A (ja) 2013-06-26 2016-08-08 グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドGuangzhou Xiangxue Pharmaceutical Co. Ltd 高安定性のt細胞受容体およびその製法と使用
JP2016525537A (ja) 2013-07-26 2016-08-25 アダプティミューネ リミテッドAdaptimmune Limited T細胞レセプター

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
CN102173056B (zh) * 2010-12-30 2014-09-03 联塑(杭州)机械有限公司 形成发泡产品的方法及其系统
JP6777841B2 (ja) * 2015-10-23 2020-10-28 国立大学法人金沢大学 細胞傷害性t細胞の作製方法
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN108117596B (zh) * 2016-11-29 2023-08-29 香雪生命科学技术(广东)有限公司 针对ny-eso的高亲和力tcr
AU2018395397A1 (en) * 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
CN110343167B (zh) * 2018-04-03 2022-10-28 香雪生命科学技术(广东)有限公司 识别ssx2抗原短肽的t细胞受体
CA3133945A1 (en) * 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500002A (ja) 2010-09-21 2014-01-09 アメリカ合衆国 抗ssx−2t細胞受容体及び関連材料並びに使用方法
JP2016523268A (ja) 2013-06-26 2016-08-08 グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドGuangzhou Xiangxue Pharmaceutical Co. Ltd 高安定性のt細胞受容体およびその製法と使用
JP2016525537A (ja) 2013-07-26 2016-08-25 アダプティミューネ リミテッドAdaptimmune Limited T細胞レセプター

Also Published As

Publication number Publication date
US20210395330A1 (en) 2021-12-23
EP3858852B1 (en) 2023-06-21
CN110950949A (zh) 2020-04-03
EP3858852A1 (en) 2021-08-04
WO2020063488A1 (zh) 2020-04-02
US11649270B2 (en) 2023-05-16
EP3858852A4 (en) 2022-06-15
JP2022502056A (ja) 2022-01-11
CN110950949B (zh) 2022-04-05
CA3114451A1 (en) 2020-04-02
EP3858852C0 (en) 2023-06-21

Similar Documents

Publication Publication Date Title
JP7556583B2 (ja) Kras突然変異を識別するt細胞受容体およびそのコード配列
CN110950949B (zh) 一种识别ssx2抗原的t细胞受体
CN106632660B (zh) 识别ny-eso-1抗原短肽的tcr
JP7429455B2 (ja) Afp抗原を識別するt細胞受容体
CN106478809B (zh) 识别prame抗原短肽的tcr
CN106188275A (zh) 识别ny-eso-1抗原短肽的t细胞受体
CN106478807B (zh) 识别mage-a3的t细胞受体
CN110343167B (zh) 识别ssx2抗原短肽的t细胞受体
CN106632658B (zh) 识别ny-eso-1抗原短肽的tcr
CN110343166A (zh) 识别afp抗原短肽的t细胞受体
CN110577591B (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
CN106478808B (zh) 识别ny-eso-1抗原短肽的t细胞受体
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
WO2021022447A1 (zh) 识别afp抗原短肽的t细胞受体
JP7429462B2 (ja) Ssx2抗原の短いペプチドを識別するt細胞受容体
WO2021170117A1 (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
TW202140532A (zh) 一種辨識afp的t細胞受體及其編碼序列
TW202144401A (zh) 一種辨識afp的t細胞受體
CN110627894B (zh) 识别ny-eso-1抗原短肽的t细胞受体及其编码序列
CN110577590A (zh) 一种识别afp抗原的tcr及其编码核酸
CN110407926B (zh) 一种识别lmp1抗原短肽的tcr及其编码序列
WO2022262835A1 (zh) 一种识别afp抗原的tcr及其编码序列
CN118812697A (zh) 一种识别kras突变的tcr及其编码序列
WO2021035446A1 (zh) 一种识别afp抗原短肽的t细胞受体及其编码序列
CN115677847A (zh) 一种识别ssx2的t细胞受体及其编码序列

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240229

R150 Certificate of patent or registration of utility model

Ref document number: 7452880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150